MGCD 290
Alternative Names: Antifungal Hos2 histone deacetylase (HDAC) enzyme inhibitor (MGCD290); MG-3290; MGCD-290Latest Information Update: 25 Jan 2024
Price :
$50 *
At a glance
- Originator MethylGene
- Class Antifungals; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Mycoses; Vulvovaginal candidiasis
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 28 Mar 2014 MGCD 290 is available for licensing in World as of 28 Mar 2014. http://mirati.com/
- 31 Dec 2013 Suspended - Phase-I for Mycoses (in volunteers) in Canada (PO)